Samsung C&T (028260) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
10 Mar, 2026Executive summary
4Q 2024 consolidated sales reached KRW 9,993 bn, down 3% sequentially but nearly flat year-over-year; full-year 2024 sales were KRW 42,103 bn, up slightly from 2023.
Operating profit for 4Q 2024 was KRW 635 bn, down 14% sequentially but up 1% year-over-year; full-year operating profit rose to KRW 2,984 bn.
Net profit for 4Q 2024 was KRW 656 bn, up 17% sequentially and 15% year-over-year; full-year net profit was KRW 2,772 bn.
Financial highlights
Gross profit for 4Q 2024 was KRW 1,834 bn, up 7% sequentially and 11% year-over-year.
SG&A expenses increased to KRW 1,199 bn in 4Q 2024, up 23% sequentially and 16% year-over-year.
Operating margin for 4Q 2024 was 6.4%, down from 7.1% in 3Q 2024 but up from 6.2% in 4Q 2023.
Non-operating profit in 4Q 2024 was KRW 137 bn, up significantly from 3Q 2024 and 4Q 2023.
Outlook and guidance
2025 revenue is expected to remain stable year-over-year, supported by a diversified business portfolio.
E&C sales are projected to decline due to completion of large projects, while T&I and F&B are forecast to grow; Bio sales volume is expected to expand with Plant 4's full operation.
New orders in E&C are targeted to increase, focusing on tech-driven products and new businesses.
Latest events from Samsung C&T
- H1 2024 net profit reached ₩1.3 trillion on ₩21.8 trillion revenue, led by bio and construction.028260
Q2 202423 Jun 2026 - Nine-month revenue reached ₩32.1T, with strong bio and F&B growth and stable capital structure.028260
Q3 202423 Jun 2026 - Net profit rose 14% year-over-year as Bio and T&I growth offset declines in other segments.028260
Q1 202523 Jun 2026 - H1 2025 revenue KRW 19.76T, net income KRW 1.09T, strong bio/construction, Bio outlook raised.028260
Q2 202523 Jun 2026 - Nine-month revenue hit KRW 29.91 trillion, led by bio growth and strong liquidity.028260
Q3 202523 Jun 2026 - Q1 2026 profit and revenue rose, driven by trading and bio, with strong cash flow and liquidity.028260
Q1 202622 Jun 2026 - Net profit surged YoY in 4Q25, with Bio and E&C driving growth and a positive 2026 outlook.028260
Q4 202510 Mar 2026